SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced a development timeline for its LymPro Blood Test for Alzheimer’s disease (“LymPro”). LymPro is designed to diagnose Alzheimer’s disease by identifying immune-based biomarkers in the blood of Alzheimer’s patients, allowing physicians to definitively differentiate Alzheimer’s disease from other forms of dementia, a key unmet medical need in the management of Alzheimer’s patients. Human clinical studies for LymPro with over 160 patients have been completed to date, showing high sensitivity and specificity for Alzheimer’s disease diagnosis.
